Download in electronic PDF format for $25

Kalchem International - Chemicals and Compounding Supplies

Search the Complete Journal Archives

Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride Injection and Dexamethasone Sodium Phosphate Injection

Author(s):  Wu George, Powers Dan, Yeung Stanley, Chen Frank

Issue:  Jan/Feb 2018 - Volume 22, Number 1
View All Articles in Issue

Abstract:  Prophylaxis or therapy with a combination of a neurokinin 1 (NK-1) receptor antagonist (RA), a 5-hydroxytryptamine-3 (5-HT3) RA, and dexamethasone is recommended by international antiemesis guidelines for the prevention of chemotherapy-induced nausea and vomiting for patients receiving highly emetogenic chemotherapy and for selected patients receiving moderately emetogenic chemotherapy. VARUBI (rolapitant) is a substance P/NK-1 RA that was recently approved by the U.S. Food and Drug Administration as an injectable emulsion in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. Palonosetron is one of the 5-HT3 RAs indicated for the prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. Herein, we describe the physical and chemical compatibility and stability of VARUBI injectable emulsion (166.5 mg/92.5 mL [1.8 mg/mL, free base], equivalent to 185 mg of rolapitant hydrochloride) admixed with palonosetron injection 0.25 mg free base in 5 mL (equivalent to 0.28 mg hydrochloride salt) and with either 5 mL (20 mg) or 2.5 mL (10 mg) of dexamethasone sodium phosphate. Admixtures were prepared and stored in VARUBI injectable emulsion ready-to-use glass vials as supplied by the rolapitant manufacturer and in four types of commonly used intravenous administration (tubing) sets. Assessment of the physical and chemical compatibility and stability of the admixtures in the VARUBI ready-to-use vials stored at room temperature (20°C to 25°C) under fluorescent light and under refrigeration (2°C to 8°C protected from light) was conducted at 0, 1, 6, 24, and 48 hours, and that of the admixtures in the intravenous tubing sets was evaluated at 0, 2, and 6 hours of storage at 20°C to 25°C. Physical stability was evaluated by visual examination of the container contents under normal room light, and measurement of turbidity, globule size, and particulate matter. Chemical stability was assessed by measuring the pH of the admixture and determining drug concentrations (potency) and impurity levels by high-performance liquid chromatographic analysis. All samples were physically and chemically compatible throughout the study duration. The pH, turbidity, globule size, and particulate matter of the admixture stayed within narrow and acceptable ranges. VARUBI injectable emulsion admixed with intravenous palonosetron and dexamethasone was chemically and physically stable in the ready-to-use glass vials for at least 24 hours at room temperature and 48 hours under refrigeration, as well as in the four selected intravenous tubing sets for at least 6 hours at room temperature. No decrease of drug concentration (or potency) of any admixed components occurred in the samples stored at the two temperature ranges and time periods studied as measured by high-performance liquid chromatographic analysis

Related Keywords: George Wu, PhD, Dan Powers, DO, Stanley Yeung, PharmD, Frank Chen, PhD, VARUBI, rolapitant, drug admixtures, neurokinin 1 receptor antagonist, 5-HT3 receptor antagonist, dexamethasone, chemotherapy-induced nausea and vomiting, emesis, antiemetic agent, palonosetron hydrochloride, substance P receptor antagonist, stability, injectable emulsion, triple combination therapy, intravenous tubing set compatibility, storage conditions

Related Categories: CANCER AND AIDS, GASTROENTEROLOGY, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, ALLERGY/IMMUNOLOGY/INFLAMMATION, NEUROLOGY

Printer-Friendly Version

Related Articles from IJPC
Title (Click for Abstract / Details) Author Issue Page View/Buy
Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride Injection and Dexamethasone Sodium Phosphate Injection Wu George, Powers Dan, Yeung Stanley, Chen Frank Jan/Feb 2018 76-85 Buy
Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Granisetron Hydrochloride Wu George, Powers Dan, Yeung Stanley, Chen Frank, Neelon Kelly Jan/Feb 2018 86-94 Buy
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate Wu George, Yeung Stanley, Chen Frank Jan/Feb 2017 66-75 Buy
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride Wu George, Yeung Stanley, Chen Frank Jan/Feb 2017 76-82 Buy
Rolapitant Injectable Emulsion with Palonosetron Hydrochloride Admixture Allen Loyd V Jr Mar/Apr 2018 151 Buy
Rolapitant Injectable Emulsion with Palonosetron Hydrochloride Admixture Allen Loyd V Jr May/Jun 2018 237 Buy
Compatibility and Stability of Palonosetron Hydrochloride with Four Neuromuscular Blocking Agents During Simulated Y-Site Administration Trusley Craig, Ben Michel, Kupiec Thomas C, Trissel Lawrence A Mar/Apr 2008 156-160 Buy
Basics of Compounding for the Treatment of Warts Allen Loyd V Jr Mar/Apr 2004 126 Buy
Compatibility and Stability of Palonosetron Hydrochloride with Gentamicin, Metronidazole, or Vancomycin During Simulated Y-Site Administration Kupiec Thomas C, Ben Michel, Trusley Craig, Trissel Lawrence A Mar/Apr 2008 170-173 Buy
Compatibility and Stability of Palonosetron Hydrochloride with Lactated Ringer's, Hetastarch in Lactated Electrolyte, and Mannitol Injections During Simulated Y-Site Administration Ben Michel, Kupiec Thomas C, Trusley Craig, Trissel Lawrence A Sep/Oct 2008 460-462 Buy